Table 1.
(a) Patient demographic characteristics and (b) clinical characteristics, concomitant conditions, and prior medications.
| Asthma (N = 1101) | COPD (N = 560) | Total (N = 1661) | p value | |
|---|---|---|---|---|
| (a) | ||||
| Gender, n (%) | ||||
| Female | 693 (62.9) | 210 (37.5) | 903 (54.4) | <0.001 |
| Male | 408 (37.1) | 350 (62.5) | 758 (45.6) | |
| Age at study visit, years | ||||
| Mean (SD) | 53.8 (16.7) | 69.5 (9.0) | 59.1 (16.3) | <0.001 |
| BMI, kg/m2 | ||||
| Mean (SD) | 28.1 (6.1) | 27.8 (5.9) | 28 (6.0) | 0.258 |
| Data unavailable | 71 | 26 | 97 | |
| Obesity (BMI ≥30), n (%) | ||||
| Yes | 315 (30.6) | 161 (30.1) | 476 (30.4) | 0.906 |
| No | 715 (69.4) | 373 (69.9) | 1088 (69.6) | |
| Data unavailable | 71 | 26 | 97 | |
| (b) | ||||
| Years since disease diagnosis | ||||
| Median (P25, P75) | 11 (4, 23) | 7 (4, 12) | 9 (4, 18) | <0.001 |
| Data unavailable | 14 | 4 | 18 | |
| FEV1, L | ||||
| Mean (SD) | 2.5 (0.9) | 1.5 (0.6) | 2.1 (1.0) | <0.001 |
| Data unavailable | 186 | 36 | 222 | |
| % predicted FEV1, % | ||||
| Mean (SD) | 81.7 (23.1) | 58.3 (23.6) | 73.1 (25.9) | <0.001 |
| Data unavailable | 224 | 50 | 274 | |
| Concomitant disease presence, n (%) | ||||
| Yes | 792 (73.1) | 459 (83.5) | 1251 (76.6) | <0.001 |
| No | 292 (26.9) | 91 (16.5) | 383 (23.4) | |
| Data unavailable | 17 | 10 | 27 | |
| Concomitant diseasea, n (%) | (N = 1084) | (N = 550) | (N = 1634) | |
| Cardiovascular disease | 267 (24.6) | 269 (48.9) | 536 (32.8) | <0.001 |
| Depression or anxiety disorder | 126 (11.6) | 79 (14.4) | 205 (12.5) | 0.133 |
| Allergy | 304 (28) | 26 (4.7) | 330 (20.2) | <0.001 |
| Osteoporosis | 33 (3.0) | 37 (6.7) | 70 (4.3) | <0.001 |
| Diabetes | 91 (8.4) | 84 (15.3) | 175 (10.7) | <0.001 |
| Cancer | 42 (3.9) | 53 (9.6) | 95 (5.8) | <0.001 |
| Other | 430 (39.7) | 276 (50.2) | 706 (43.2) | <0.001 |
| Any previous asthma/COPD treatment, n (%) | ||||
| Yes | 575 (56.3) | 283 (55.1) | 858 (55.9) | 0.679 |
| No | 446 (43.7) | 231 (44.9) | 677 (44.1) | |
| Data unavailable | 80 | 46 | 126 | |
| Previous asthma/COPD treatment description, n (%) | (n = 575) | (n = 283) | (n = 858) | |
| ICS monotherapy | 191 (33.2) | 23 (8.1) | 214 (24.9) | <0.001 |
| LABA monotherapy | 20 (3.5) | 21 (7.4) | 41 (4.8) | |
| Fixed-dose combination (different from current) | 287 (49.9) | 147 (51.9) | 434 (50.6) | |
| Long-acting muscarinic antagonists | 13 (2.3) | 60 (21.2) | 73 (8.5) | |
| Leukotriene modifier | 28 (4.9) | 0 (0) | 28 (3.3) | |
| Methylxanthine (theophylline) | 1 (0.2) | 5 (1.8) | 6 (0.7) | |
| Other | 35 (6.1) | 27 (9.5) | 62 (7.2) | |
| Data unavailable | 0 | 0 | 0 | |
| Duration (months) of use of the patient’s current FDCb | ||||
| Median (P25, P75) | 18.7 (8.6, 47.2) | 22.4 (10.1, 55.1) | 19.7 (9, 50.4) | 0.144 |
| Data unavailable | 225 | 130 | 355 | |
| Disease control (asthma)/Low symptom burden (COPD), n (%) | ||||
| Yes | 684 (62.4) | 85 (15.5) | 769 (46.7) | <0.001 |
| No | 412 (37.6) | 464 (84.5) | 876 (53.3) | |
| Data unavailable | 5 | 11 | 16 | |
BMI body mass index, COPD chronic obstructive pulmonary disease, FDC fixed-dose combination, FEV1 forced expiratory volume in 1 s, ICS inhaled corticosteroid, LABA long-acting beta agonist, SD standard deviation
aEvery patient may present several concomitant diseases. Thus percentages have been calculated based on the number of patients
bPatients were eligible for the study if they had received a stable dose of ICS/LABA FDC for the 3 months prior to enrolment. One COPD patient who had received treatment for 12 weeks was accepted onto the study by the sponsor